Press Release – 27.09.2017

Theraclion Extends Market Access and Regulatory Approval

 

• NICE (UK) published guidance for the use of Echopulse® in fibroadenoma
• Echopulse® achieved regulatory approval in Russia

 
THERACLION today announced that the British National Institute for Health and Clinical Excellence (NICE) has published guidance within the framework of its interventional procedure program for high-intensity focused ultrasound for symptomatic breast fibroadenoma. Theraclion also announced obtaining regulatory approval from the Russian Ministry of Health.

 

Read the press release

Print Friendly